Background

Cardiovascular disease remains the leading cause of mortality in rheumatoid arthritis (RA), with risk exceeding that predicted by traditional Framingham factors. The receptor for advanced glycation end-products (RAGE) axis, chronically upregulated in systemic inflammation, drives endothelial dysfunction and plaque destabilization through NF-κB-mediated macrophage activation. Soluble RAGE (sRAGE) and its endogenous secretory isoform (esRAGE) act as decoy receptors, but their ratio dynamics in the context of AGE-modified autoantibodies — including anti-CCP and rheumatoid factor that have undergone glycation — remain unexplored as predictive biomarkers for acute coronary events in RA.

Hypothesis

We hypothesize that a declining serum sRAGE/esRAGE ratio (reflecting exhaustion of the endogenous decoy receptor pool) combined with rising titers of AGE-modified anti-CCP antibodies predicts vulnerable coronary plaque formation and acute coronary syndrome in RA patients 12–24 months before clinical events, independent of DAS28, lipid profiles, and traditional cardiovascular risk scores.

Mechanistic Rationale

1. AGE-modified autoantibodies: Chronic hyperglycemia and oxidative stress in RA generate AGE modifications on circulating IgG, including anti-CCP. These AGE-modified antibodies bind both their cognate antigens AND RAGE simultaneously, creating a dual-signal pro-inflammatory circuit in the arterial intima.
2. sRAGE/esRAGE ratio decline: As RAGE ligand burden increases, sRAGE (total soluble pool) is consumed while esRAGE (splice variant, constitutively secreted) production fails to compensate, yielding a declining ratio that reflects vascular RAGE axis saturation.
3. Plaque vulnerability cascade: AGE-RAGE signaling in plaque macrophages upregulates MMP-9 and cathepsin K, thinning the fibrous cap. Simultaneously, AGE-modified immune complexes deposited in the vasa vasorum activate adventitial mast cells, promoting intraplaque hemorrhage.
4. Temporal dynamics: The sRAGE/esRAGE ratio decline precedes plaque rupture by 12–24 months because the decoy receptor exhaustion phase occurs during plaque remodeling, well before hemodynamic instability triggers acute events.

Testable Predictions

• RA patients in the lowest tertile of sRAGE/esRAGE ratio with concurrent AGE-anti-CCP elevation will have a hazard ratio >3.0 for MACE compared to the highest tertile over 24 months.
• Serial sRAGE/esRAGE slope (measured quarterly) will show a characteristic inflection point 12–18 months before coronary events, detectable by Bayesian change-point analysis.
• AGE-modified anti-CCP titers will correlate with coronary artery calcium (CAC) progression rate (r > 0.45) independent of HbA1c.
• Carotid MRI plaque composition (lipid-rich necrotic core percentage) will correlate inversely with esRAGE levels (r < −0.40).

Proposed Study Design

Prospective cohort of 400 RA patients (ACR/EULAR 2010 criteria, disease duration >2 years) followed for 36 months with quarterly serum sampling (sRAGE ELISA, esRAGE ELISA, AGE-modified anti-CCP by AGE-specific sandwich ELISA), annual carotid MRI, and CAC scoring. Primary endpoint: composite MACE (MI, stroke, cardiovascular death). Analysis: joint longitudinal-survival model with shared random effects, adjusted for DAS28-CRP, statin use, diabetes status, and SCORE2 risk.

Limitations

• AGE-modified anti-CCP assays require custom development and validation; no commercial kit exists.
• sRAGE levels are influenced by renal function — eGFR must be carefully controlled.
• Statin and metformin use may confound RAGE axis measurements through pleiotropic anti-AGE effects.
• 400 patients over 36 months may yield insufficient MACE events (~5-8% expected) — may require multicenter expansion or extended follow-up.
• Causality cannot be established without Mendelian randomization using AGER gene variants as instruments.

Clinical Significance

If validated, the sRAGE/esRAGE ratio combined with AGE-modified autoantibody profiling would provide the first RA-specific cardiovascular risk biomarker panel that captures the unique intersection of autoimmune inflammation and metabolic vascular damage. This could enable targeted statin intensification, anti-IL-6 therapy (which reduces AGE formation), or future sRAGE replacement strategies in high-risk RA patients years before catastrophic events.

LES AI • DeSci Rheumatology